02/20/2022

A NOVEL METHOD FOR HANDLING PRE-EXISTING CONDITIONS IN PREDICTION MODELS FOR COVID-19 DEATH

Glen H. Murata, MD*

Allison E. Murata, MSIM^

Heather M. Campbell, PharmD, PhD^&

Benjamin H. McMahon, PhD%

Jenny T. Mao, MD, FCCP*#

* New Mexico VA Health Care System, Albuquerque NM

^ VA Cooperative Studies Program - Clinical Research Pharmacy Coordinating Center,
Albuquerque NM

& University of New Mexico College of Pharmacy, Albuquerque NM

% Los Alamos National Laboratory, Los Alamos NM

University of New Mexico School of Medicine, Albuquerque NM

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

2

ABSTRACT

Objective: To derive a predicted probability of death (PDeathDx) based upon complete sets of ICD-10 codes assigned to patients prior to their diagnosis of COVID-19. PDeathDx is intended for use as a summary metric for pre-existing conditions in multivariate models for COVID-19 death.

Methods: Cases were identified through the COVID-19 Shared Data Resource (CSDR) of the Department of Veterans Affairs. The diagnosis required at least one positive nucleic acid amplification test (NAAT). The primary outcome was death within 60 days of the first positive test. We retrieved all diagnoses entered into the electronic medical record for visits, on problem lists, and at the time of hospital discharge if they were at least 14 days prior to the NAAT. ICD-9 codes were converted to ICD-10 equivalents using a crosswalk provided by the Centers for Medicare/Medicaid Services. ICD-10 codes were converted to their category diagnoses defined as all columns to the left of the decimal point. Each patient was considered to have or not have each category diagnosis prior to the NAAT. A computer program calculated the number of cases for each category diagnosis, the relative risk (RR) of death, and its confidence interval (CI) using a Bonferroni adjustment for multiple comparisons. RRs were re-centered by subtracting 1 so that high-risk conditions had a positive value while protective conditions had a negative one. Diagnoses found to be significant were entered into a logistic model for death in a stepwise fashion. Each patient was assigned (RR-1) to each category diagnosis if they had the condition or 0 otherwise. The resulting model was used to derive PDeathDx for each patient and the area under its receiver operating characteristic (ROC) curve calculated. Single variable logistic models were also derived for age at diagnosis, the Charlson 2-year (Charl2Yr) and lifetime (CharlEver) scores, and the Elixhauser 2-year (Elix2Yrs) and lifetime (ElixEver) scores. Stata was used to compare the ROCs for PDeathDx and each of the other metrics.

Results: On September 30, 2021 there were 347,220 COVID-19 patients in the CSDR. 18,120 patients (5.33%) died within 60 days of their diagnosis. After consolidating ICD-9 and ICD-10

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

3

codes, 29,162,710 separate diagnoses were given to the subjects representing 41,341 ICD-10 codes. This set was reduced to 1,890 category diagnoses assigned to the group for the first time on 19,184,437 occasions. Of the 1,890 category diagnoses, 425 involved ≥ 100 subjects and had a lower boundary for the CI ≥ 1.50 (a high-risk condition) or upper boundary ≤ 0.80 (a protective condition). Stepwise logistic regression showed that 153 were statistically significant, independent predictors of death. PDeathDx was slightly less powerful than age as a discriminator (ROC = 0.811 $\pm$ 0.002 vs 0.812 $\pm$ 0.001, respectively; $P < 0.001$) but was superior to the Charl2Yr (ROC = 0.727 $\pm$ 0.002; $P < 0.001$), CharlEver (ROC = 0.753 $\pm$ 0.002; $P \leq 0.001$), Elix2Yr (ROC = 0.694 $\pm$ 0.002; $P < 0.001$); and ElixEver (ROC = 0.731 $\pm$ 0.002; $P < 0.001$). Univariate analysis and multivariate modeling showed that many of the most high-risk conditions are under-represented or not included in the Charlson Index. These include hypertension, dementia, degenerative neurologic disease, or diagnoses associated with severe physical disability.

Conclusions: Our method for handling pre-existing conditions in multivariate analysis has many advantages over conventional comorbidity indices. The approach can be applied to any condition or outcome, can use any categorical predictors including medications, creates its own condition weights, handles rare as well as protective conditions, and returns actionable information to providers. The latter include the specific ICD-10 groups, their contribution to the risk, and their rank order of importance. Finally, PDeathDx is equivalent to age as a discriminator of outcomes and outperforms 4 other comorbidity scores. If validated by others, this approach provides an alternative and more robust approach to handling comorbidities in multivariate models.

INTRODUCTION

Many mathematical models have been proposed for predicting death from COVID-19 infection (1-5). They have gained popularity because they are very useful for managing patients and allocating scarce resources. One of the most important components of these models is the set of pre-existing conditions. Many diseases increase the mortality rate because they diminish the host response to infection, cause end-organ dysfunction that is further compromised by COVID-19, or severely limit life expectancy and functional status. One method for handling these conditions is to gather them under broad categories (“malignancy”) and derive a regression coefficient for each grouping (3, 4). Another approach is to use a comorbidity scoring system such as the Charlson Comorbidity Index (CCI) or Elixhauser (ELIX) score (1, 2, 5). With this approach, the groupings are assigned weights, and the weights are added to generate a summary score. The summary score is then used as a covariate in the model. CCI and ELIX have been extensively validated and applied to many conditions (6). Moreover, mathematical modeling has shown that they provide all that is necessary to handle confounding from the underlying diagnoses (7). However, there are still problems with either approach:

- 1) CCI was developed to predict mortality one year after hospitalization. It is less clear that the same conditions are the most influential for outcomes mediated by an immune response such as breakthrough infections.
- 2) Rare diseases are not well represented. As a result, a person with a common disease of limited impact could be given a poorer prognosis than another with a rare but lethal condition.
- 3) There is often little evidence that members of each group have the same prognostic significance.
- 4) Neither method handles conditions that are protective.
- 5) These approaches do not return actionable information to clinicians. While they may become aware of their patients’ risk, providers are not informed of the sources of such

risk. As a result, they cannot take steps to mitigate that risk through further studies or treatments.

A more sophisticated approach is to do a systematic survey of all pre-existing conditions, determine which have an impact on outcomes, and generate a predicted probability of death that represents the aggregate risk posed by those that are statistically significant. Like a propensity score, this predicted probability of death (PDeathDx) can be used as a variable in the model. Fortunately, advanced computer methods have made it possible to generate these estimates. The purpose of this study is to describe a novel approach to handling comorbidities in COVID-19 prediction models and compare the performance of PDeathDx with conventional comorbidity measures in distinguishing fatal from non-fatal cases.

METHODS

Cases were identified through VA's COVID-19 Shared Data Resource (CSDR). Membership in this registry requires at least one positive nucleic acid amplification test (NAAT). The primary outcome was death within 60 days of the diagnosis. The outcome was retrieved from the post-index conditions file of the CSDR, which assigns a 1 to those who died and 0 otherwise. Likewise, the 2-year CCI score (Charl2Yrs), lifetime CCI score (CharlEver), 2-year ELIX score (Elix2Yrs), and lifetime ELIX score (ElixEver) were retrieved from CSDR for each patient. Pre-existing conditions were identified by reviewing all diagnoses entered into the electronic medical record for outpatient visits, on patient problem lists, or at the time of hospital discharge. "Pre-existing" refers to entries made at least 14 days prior to the diagnosis of COVID-19. This precaution excludes any entries that may have been made during the pre-symptomatic phases of COVID-19. ICD-9 codes were converted to ICD-10 using a crosswalk provided by the Centers for Medicare/Medicaid Services. A "category diagnosis" was defined as all characters preceding the decimal point for ICD-10 codes or the ICD-9 equivalent. A patient was considered to have or not have each category condition prior to the COVID diagnosis. A computer program was used to identify all patients with a given condition who died

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

6

or survived as well as all patients without the condition who died or survived. The software used these cell frequencies to derive the relative risk of death associated with the condition (RR) and its confidence interval (CI). CI were adjusted for multiple comparisons by the Bonferroni method. A category diagnosis was considered to have a significant effect on the outcome if there were at least 100 cases and if the lower limit for the CI was ≥ 1.5 or the upper limit was ≤ 0.80 . Another software program was used to create a diagnostic grid in which each patient was assigned a value for all significant category diagnoses. Recall that a condition with a relative risk of 1 has no effect on the outcome. The scale for relative risk was therefore centered on 1 by subtracting 1 from the relative risk and entering that value for the corresponding category condition if present. Those without the condition were treated as if they had a condition with no prognostic significance and assigned a value of 0. The diagnostic grid was exported to a statistical program (Stata). Stepwise logistic regression was used to identify those that were independently predictive of death. This procedure adjusted the contribution of each condition for the presence of the others, assigned a predicted probability of death to each patient (PDeathDx), and used PDeathDx to generate an area under a Receiver Operating Characteristic curve (ROC area). The product of coefficient * (RR - 1) is the contribution of each condition to the logit function if present. It was therefore used to rank order the importance of the category diagnoses. Differences in categorical variables were tested by chi-square analysis; differences in continuous variables were analyzed by the unpaired student's t-test or rank sum test. Separate logistic models were used to examine the effect of age, Charl2Yrs, CharlEver, Elix2Yrs, and ElixEver as single predictors of death. Stata provides a function that compares the ROC areas for pairs of these variables.

RESULTS

On September 30, 2021, there were 347,220 COVID-19 patients in VA's COVID-19 Shared Data Resource. 339,772 (or 97.9%) had at least one pre-existing condition and form the basis for this report. The mean age at the time of diagnosis was 58.6 ± 16.7 years; 84.1%

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

7

were male; 22.9% were members of a racial minority; 9.0% were Hispanic; 95.8% were veterans; 0.7% were on supplemental oxygen; and 11.8% were current smokers. 9.1% had been fully vaccinated at least 14 days prior to the COVID-19 diagnosis. 21.5% acquired their infections after July 1, 2021 and were presumed to have the delta variant. Overall, 18,120 patients (5.33%) died within 60 days of their diagnosis.

For the study cohort, 82,578,233 ICD-9 codes had been entered into the electronic record before the VA converted to ICD-10 codes in 2015. Of these, 81,671,483 (or 98.9%) were successfully converted to an ICD-10 equivalent using the CMS crosswalk. In addition, 78,976,269 ICD-10 codes were entered at least 14 days prior to the COVID-19 diagnosis. After consolidation, 29,162,710 separate diagnoses were given to the subjects representing 41,341 ICD-10 codes. The sample size was insufficient to test each ICD-10 code for its prognostic significance. The individual codes were therefore reduced to 1,890 category diagnoses which were assigned to the group for the first time on 19,184,437 occasions.

Of the 1,890 category diagnoses, 425 involved ≥ 100 subjects and had a lower boundary for the CI ≥ 1.50 or upper boundary ≤ 0.80 (Table 1). One diagnosis (Z11: screening for other viral diseases) was given to 120,308 subjects and had a high RR for death; it was removed because it may have been used for COVID-19 testing before there was a suitable ICD-10 code. Preliminary regressions indicated that another 26 provided a perfect prediction of the outcome when present, while 20 were affected by collinearity. A diagnostic grid was therefore assembled where each patient was assigned a value for each of the remaining 378 category diagnoses. If the diagnosis was present, (RR – 1) was assigned as its value and 0 otherwise. Stepwise logistic regression showed that 153 were statistically significant, independent predictors of death (Table 2). PDeathDx was derived for each patient and its ROC area determined. This analysis showed that PDeathDx provided excellent discrimination between those who died and those who survived (ROC area = 0.811 ± 0.002). Single variable logistic models were also constructed for age at diagnosis, Charl2Yrs, CharlEver, Elix2Yrs, and

ElixEver, and ROC areas determined for their predicted probabilities. PDeathDx was less powerful than age as a discriminator (ROC = 0.812 ± 0.001 ; $P < 0.001$) but was superior to the Charl2Yr (ROC = 0.727 ± 0.002 ; $P < 0.001$), CharlEver (ROC = 0.753 ± 0.002 ; $P \leq 0.001$), Elix2Yr (ROC = 0.694 ± 0.002 ; $P < 0.001$); and ElixEver (ROC = 0.731 ± 0.002 ; $P < 0.001$).

Tables 1 and 2 show that this approach provides much more clinical information than the indices. Table 1 ranks the category diagnoses by their RR on univariate analysis.

Degenerative neurologic disease and severe functional disability are prominently represented within the top 20 most influential conditions. This observation is significant because they are not given much weight in comorbidity indices. On the other hand, only one solid tumor (carcinoma of the ampulla of Vater) appears within the top 20. On the other end of the scale, several functional diagnoses, gynecologic disorders, and sexually transmitted diseases reduced the risk of death. Table 2 shows the ICD-10 codes that were independently predictive of death rank ordered by their contribution to the logit when present. Many high-risk conditions became protective when adjusted for the effects of others. Hypertension was the most important independent risk factor for death and represented a greater threat than coronary artery disease. Degenerative neurologic diseases were prominently represented at the top of the list, while malignancies comprised the bulk of high-risk conditions.

DISCUSSION

We propose a novel method for handling pre-existing conditions in COVID prediction models that has several theoretical advantages over conventional comorbidity indices. Table 3 compares the attributes of the standard comorbidity indices and PDeathDx. Unlike a standard index, our approach creates a different model for every disease. The outcome can be changed by re-defining a target group. Univariate statistical analysis is used to assign condition weights. The method can be applied to any type of categorical predictor including medications and procedures. It handles rare as well as protective conditions. In addition to identifying high-risk codes, the output includes a probability for each pattern of conditions. It can therefore detect

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

9

circumstances where disease combinations are problematic. Finally, the model can be used to return actionable information to providers. Instead of total or condition scores, this information includes the predicted probability of the outcome, the specific diagnoses contributing to the prediction, and their rank order of importance. Such information may prompt the provider to explore a mechanism of injury or an intervention to mitigate the risk.

However, PDeathDx requires programming at a high level, takes more time, and uses more computing resources. The first hurdle is the systematic search for candidate diagnoses among millions of entries in the electronic record and performing screening statistical tests on thousands of root diagnoses. The second is creating a diagnostic array in which each patient is given a score for every significant diagnosis experienced by the cohort. The table must then be transferred to a statistical program capable of handling hundreds of predictors and large number of rows.

PDeathDx provided powerful discrimination between COVID-19 patients who died and survived, out-performed the other comorbidity indices, had an ROC area equivalent to that generated by age, and remains the second most powerful predictor of all those that we have examined thus far. The most influential category conditions included entries not usually included in comorbidity indices. This observation suggests that it is risky to pick comorbidities for analysis without a systematic review of all those experienced by the cohort. Moreover, poor prognoses were assigned to those with dementia, degenerative neurological diseases, and severe disabilities – conditions not usually associated with cardiorespiratory injury or impaired immunity. These disorders are often associated with a poor quality of life that dictates a conservative approach to treatment. If this decision is common for COVID-19 patients, then death may be more indicative of the patient's baseline condition than severity of illness. In that event, this outcome may not be suitable for studies of interventions. Finally, multivariate analysis showed that some high-risk conditions became protective when adjusted for the effect

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

10

of other components of the model. It would have been a mistake to treat the effect of these conditions as independent and additive.

We did not include age in our model for PDeathDx for 3 reasons. First, it was intended to represent pre-existing conditions in an overarching model containing multiple domains. One domain was comprised of demographic characteristics including age at diagnosis. Next, we did not want age to displace the diagnoses highly correlated with age in the model. To understand the mechanisms that lead to a fatal outcome, explanatory variables should take precedence over disease markers. If age is modelled at all, it should be for a residual effect once causal factors have been included. Finally, age-based models do not support decision-making at the point of care. For example, a physician might feel comfortable withdrawing care if the patient had Alzheimer's disease – but not simply because the patient was old. Clinicians make recommendations based upon an assessment of the underlying conditions. It is the patient's prerogative to decide what is appropriate based upon age and quality of life.

We included all diagnoses in the medical record because some conditions have an effect over the patient's lifetime even if they have not been recently active. Examples include intravenous drug use or sickle cell trait. We also wanted to test our computing resources to see if they were capable of handling problems of this size. Finally, to develop the most efficient model, it is reasonable to start with a comprehensive list of diagnoses and work backwards. That strategy allows one to determine if time-limited sampling compromises the ability of PDeathDx to discriminate between survivors and non-survivors. On the other hand, starting with a fixed time frame for diagnoses is arbitrary and provides no information about the benefits of more remote data. Fortunately, our computing resources were more than sufficient to handle all pre-existing conditions.

The major limitation of our approach is that it handles all pre-existing diagnoses – not just the most recent ones. Thus, a person with chronic renal failure (CRF) who undergoes a transplant and regains normal renal function will still be included in the analysis of CRF. Of

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

11

course, our conclusions are limited to patients with characteristics like the veteran population.

Further studies should be done on other populations and disease states before the method should be widely applied. If validated by others, our method could provide a more robust alternative to comorbidity scores for handling pre-existing conditions in multivariate models.

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

12

TABLE 1: ICD-10 CATEGORY DIAGNOSES PREDICTIVE OF DEATH ON UNIVARIATE ANALYSIS

** Most Common ICD-10 Code and Description for Each Category Diagnosis*

Root ICD-10	ICD-10 Code*	ICD-10 Description*	No. of Cases	Case Rate	Control Rate	Relative Risk	Lower CI	Higher CI
G30	G30.9	Alzheimer's disease, unspecified	4348	0.2672	0.0506	5.2861	4.7347	5.9017
F03	F03.90	Unspecified dementia without behavioral disturbance	13895	0.2340	0.0456	5.1278	4.7678	5.5150
F02	F02.80	Dementia in oth diseases classd elswhr w/o behavrl disturb	8684	0.2379	0.0485	4.9065	4.4977	5.3524
I10	I10.	Essential (primary) hypertension	208817	0.0768	0.0159	4.8387	4.3920	5.3309
F01	F01.50	Vascular dementia without behavioral disturbance	6033	0.2342	0.0501	4.6786	4.2212	5.1856
Z66	Z66.	Do not resuscitate	6448	0.2244	0.0500	4.4864	4.0498	4.9700
R62	R62.7	Adult failure to thrive	3414	0.2209	0.0516	4.2777	3.7238	4.9140
R54	R54.	Age-related physical debility	11357	0.1983	0.0483	4.1040	3.7668	4.4714
C93	C93.10	Chronic myelomonocytic leukemia not achieve remission	122	0.2131	0.0533	4.0005	1.9240	8.3180
D46	D46.9	Myelodysplastic syndrome, unspecified	755	0.2106	0.0530	3.9750	2.9513	5.3539
L89	L89.90	Pressure ulcer of unspecified site, unspecified stage	8092	0.1908	0.0500	3.8180	3.4499	4.2253
I13	I13.0	Hyp hrt & chr kdny dis w hrt fail and stg 1-4/unsp chr kdny	9823	0.1844	0.0494	3.7299	3.3925	4.1008
J64	J64.	Unspecified pneumoconiosis	107	0.1963	0.0533	3.6833	1.6173	8.3882
C95	C95.90	Leukemia, unspecified not having achieved remission	609	0.1938	0.0531	3.6505	2.5754	5.1743
R64	R64.	Cachexia	797	0.1932	0.0530	3.6457	2.6851	4.9499
E43	E43.	Unspecified severe protein-calorie malnutrition	1597	0.1904	0.0527	3.6133	2.9023	4.4984
Z74	Z74.09	Other reduced mobility	17940	0.1681	0.0469	3.5822	3.3154	3.8704
D63	D63.1	Anemia in chronic kidney disease	14823	0.1703	0.0480	3.5494	3.2667	3.8565
C24	C24.1	Malignant neoplasm of ampulla of Vater	122	0.1885	0.0533	3.5383	1.6054	7.7983
F05	F05.	Delirium due to known physiological condition	3612	0.1822	0.0519	3.5070	3.0142	4.0803
Y95	Y95.	Nosocomial condition	355	0.1859	0.0532	3.4952	2.1891	5.5806
W06	W06.XX XA	Fall from bed, initial encounter	2167	0.1832	0.0525	3.4898	2.8768	4.2334
C78	C78.7	Secondary malig neoplasm of liver and intrahepatic bile duct	1305	0.1839	0.0528	3.4814	2.7193	4.4570
J90	J90.	Pleural effusion, not elsewhere classified	5673	0.1754	0.0513	3.4218	3.0197	3.8774
J69	J69.0	Pneumonitis due to inhalation of food and vomit	2896	0.1785	0.0523	3.4165	2.8812	4.0511
I50	I50.9	Heart failure, unspecified	36427	0.1447	0.0424	3.4162	3.2021	3.6445
N18	N18.9	Chronic kidney disease, unspecified	48428	0.1352	0.0397	3.4042	3.2006	3.6206
I75	I75.029	Atheroembolism of unspecified lower extremity	138	0.1812	0.0533	3.4003	1.5879	7.2814
J81	J81.0	Acute pulmonary edema	2462	0.1767	0.0524	3.3700	2.7995	4.0567
G20	G20.	Parkinson's disease	5105	0.1732	0.0515	3.3623	2.9456	3.8379
N25	N25.81	Secondary hyperparathyroidism of renal origin	6475	0.1699	0.0511	3.3268	2.9515	3.7497
J96	J96.01	Acute respiratory failure with hypoxia	13350	0.1624	0.0489	3.3231	3.0408	3.6316

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

13

I12	I12.9	Hypertensive chronic kidney disease w stg 1-4/unsp chr kdny	26422	0.1498	0.0452	3.3156	3.0895	3.5582
D02	D02.20	Carcinoma in situ of unspecified bronchus and lung	2023	0.1740	0.0526	3.3075	2.6919	4.0639
W07	W07.XX XA	Fall from chair, initial encounter	1948	0.1740	0.0526	3.3063	2.6807	4.0780
C94	C94.6	Myelodysplastic disease, not classified	412	0.1748	0.0532	3.2860	2.0929	5.1592
N19	N19.	Unspecified kidney failure	7383	0.1663	0.0508	3.2729	2.9203	3.6680
L12	L12.0	Bullous pemphigoid	334	0.1737	0.0532	3.2634	1.9740	5.3952
R26	R26.9	Unspecified abnormalities of gait and mobility	67067	0.1202	0.0369	3.2578	3.0675	3.4598
Z49	Z49.31	Encounter for adequacy testing for hemodialysis	1540	0.1714	0.0528	3.2472	2.5607	4.1178
I96	I96.	Gangrene, not elsewhere classified	2079	0.1708	0.0526	3.2459	2.6429	3.9864
H27	H27.8	Other specified disorders of lens	6825	0.1642	0.0511	3.2170	2.8561	3.6236
I25	I25.10	Atherosclerotic heart disease of native coronary artery w/o ang pctrs	77259	0.1139	0.0355	3.2083	3.0212	3.4069
T66	T66.XXX A	Radiation sickness, unspecified, initial encounter	211	0.1706	0.0533	3.2036	1.6912	6.0686
C34	C34.90	Malignant neoplasm of unsp part of unsp bronchus or lung	3805	0.1664	0.0520	3.1962	2.7354	3.7346
E46	E46.	Unspecified protein-calorie malnutrition	3568	0.1659	0.0521	3.1825	2.7098	3.7377
E44	E44.0	Moderate protein-calorie malnutrition	3752	0.1647	0.0521	3.1623	2.7011	3.7022
C91	C91.10	Chronic lymphocytic leuk of B-cell type not achieve remis	1854	0.1661	0.0527	3.1517	2.5270	3.9307
N17	N17.9	Acute kidney failure, unspecified	31785	0.1396	0.0444	3.1421	2.9347	3.3641
Z19	Z19.2	Hormone resistant malignancy status	174	0.1667	0.0533	3.1286	1.5331	6.3847
L22	L22.	Diaper dermatitis	774	0.1654	0.0531	3.1159	2.2159	4.3814
G91	G91.2	(Idiopathic) normal pressure hydrocephalus	917	0.1647	0.0530	3.1053	2.2680	4.2515
G92	G92.	Toxic encephalopathy	1085	0.1631	0.0530	3.0793	2.3025	4.1180
Y73	Y73.2	Prosth/oth implnt/mtrls gastroent and urol dev assoc w incdt	735	0.1633	0.0531	3.0752	2.1619	4.3743
C79	C79.51	Secondary malignant neoplasm of bone	2724	0.1612	0.0525	3.0721	2.5499	3.7014
Z96	Z96.1	Presence of intraocular lens	58557	0.1206	0.0393	3.0656	2.8838	3.2588
E78	E78.5	Hyperlipidemia, unspecified	223873	0.0692	0.0226	3.0600	2.8037	3.3397
I73	I73.9	Peripheral vascular disease, unspecified	31350	0.1369	0.0448	3.0545	2.8506	3.2730
R18	R18.8	Other ascites	2408	0.1586	0.0526	3.0172	2.4710	3.6840
C66	C66.9	Malignant neoplasm of unspecified ureter	237	0.1603	0.0533	3.0107	1.6104	5.6286
Z95	Z95.1	Presence of aortocoronary bypass graft	34407	0.1330	0.0444	2.9986	2.8020	3.2089
Z71	Z71.89	Other specified counseling	308757	0.0568	0.0190	2.9898	2.5115	3.5592
J91	J91.8	Pleural effusion in other conditions classified elsewhere	4873	0.1545	0.0519	2.9798	2.5795	3.4422
G11	G11.1	Early-onset cerebellar ataxia	586	0.1570	0.0532	2.9538	1.9729	4.4224
I48	I48.91	Unspecified atrial fibrillation	35951	0.1301	0.0442	2.9419	2.7502	3.1470
J15	J15.9	Unspecified bacterial pneumonia	9858	0.1482	0.0505	2.9350	2.6389	3.2644
N14	N14.0	Analgesic nephropathy	405	0.1556	0.0532	2.9235	1.7952	4.7611
I67	I67.89	Other cerebrovascular disease	16692	0.1420	0.0487	2.9125	2.6714	3.1754
H26	H26.9	Unspecified cataract	60786	0.1156	0.0398	2.9053	2.7326	3.0889

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

14

Y71	Y71.2	Prosth/oth implnt/mtrls cardiovascular devices assoc w incdt	989	0.1537	0.0530	2.8978	2.1144	3.9715
J17	J17.	Pneumonia in diseases classified elsewhere	2185	0.1524	0.0527	2.8925	2.3345	3.5838
J61	J61.	Pneumoconiosis due to asbestos and other mineral fibers	1189	0.1531	0.0530	2.8892	2.1653	3.8551
T82	T82.818 A	Embolism due to vascular prosth dev/grft, initial encounter	6593	0.1479	0.0515	2.8738	2.5282	3.2668
I95	I95.9	Hypotension, unspecified	32131	0.1301	0.0453	2.8710	2.6771	3.0789
I70	I70.0	Atherosclerosis of aorta	19489	0.1379	0.0482	2.8613	2.6354	3.1065
I27	I27.20	Pulmonary hypertension, unspecified	9999	0.1445	0.0506	2.8580	2.5677	3.1811
W90	W90.8XX A	Exposure to other nonionizing radiation, initial encounter	250	0.1520	0.0533	2.8541	1.5219	5.3522
I62	I62.00	Nontraumatic subdural hemorrhage, unspecified	1571	0.1509	0.0529	2.8530	2.2142	3.6762
N40	N40.0	Benign prostatic hyperplasia without lower urinary tract symp	85767	0.1036	0.0363	2.8518	2.6852	3.0289
R65	R65.20	Severe sepsis without septic shock	5450	0.1468	0.0518	2.8334	2.4613	3.2617
A41	A41.9	Sepsis, unspecified organism	12759	0.1412	0.0499	2.8303	2.5681	3.1193
C83	C83.30	Diffuse large B-cell lymphoma, unspecified site	1195	0.1498	0.0530	2.8268	2.1123	3.7829
L97	L97.509	Non-pressure chronic ulcer oth prt unsp foot w unsp severity	13950	0.1401	0.0496	2.8231	2.5701	3.1010
I06	I06.0	Rheumatic aortic stenosis	614	0.1498	0.0532	2.8189	1.8796	4.2275
C92	C92.10	Chronic myeloid leuk, BCR/ABL-positive, not achieve remis	602	0.1495	0.0532	2.8123	1.8667	4.2369
G31	G31.84	Mild cognitive impairment, so stated	21486	0.1343	0.0479	2.8064	2.5905	3.0402
G70	G70.00	Myasthenia gravis without (acute) exacerbation	745	0.1490	0.0531	2.8049	1.9386	4.0581
G21	G21.11	Neuroleptic induced parkinsonism	2043	0.1478	0.0528	2.8019	2.2364	3.5103
D61	D61.818	Other pancytopenia	3153	0.1468	0.0525	2.7995	2.3311	3.3619
J70	J70.5	Respiratory conditions due to smoke inhalation	438	0.1484	0.0532	2.7891	1.7221	4.5172
R57	R57.0	Cardiogenic shock	1089	0.1478	0.0530	2.7881	2.0503	3.7914
I63	I63.9	Cerebral infarction, unspecified	18075	0.1357	0.0487	2.7853	2.5572	3.0338
C19	C19.	Malignant neoplasm of rectosigmoid junction	547	0.1481	0.0532	2.7847	1.8074	4.2903
H25	H25.13	Age-related nuclear cataract, bilateral	127537	0.0888	0.0320	2.7742	2.6054	2.9539
W08	W08.XX XA	Fall from other furniture, initial encounter	544	0.1471	0.0532	2.7653	1.7896	4.2730
Z75	Z75.1	Person awaiting admission to adequate facility elsewhere	10861	0.1394	0.0505	2.7610	2.4854	3.0672
S88	S88.119 A	Complete traum amp at lev betw kn & ankl, unsp low leg, init	1412	0.1459	0.0529	2.7556	2.0985	3.6185
J84	J84.10	Pulmonary fibrosis, unspecified	7398	0.1414	0.0514	2.7524	2.4303	3.1172
N08	N08.	Glomerular disorders in diseases classified elsewhere	2453	0.1443	0.0527	2.7400	2.2233	3.3768
I65	I65.29	Occlusion and stenosis of unspecified carotid artery	16848	0.1344	0.0491	2.7367	2.5052	2.9897
S78	S78.019 A	Complete traumatic amputation at unsp hip joint, init encntr	447	0.1454	0.0532	2.7329	1.6860	4.4299
J92	J92.9	Pleural plaque without asbestos	1007	0.1450	0.0531	2.7326	1.9780	3.7751
I69	I69.898	Other sequelae of other cerebrovascular disease	14535	0.1356	0.0497	2.7310	2.4866	2.9995

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

15

D64	D64.9	Anemia, unspecified	62258	0.1103	0.0405	2.7201	2.5576	2.8930
S72	S72.009 A	Fracture of unsp part of neck of unsp femur, init	3337	0.1423	0.0524	2.7140	2.2641	3.2535
C80	C80.1	Malignant (primary) neoplasm, unspecified	1345	0.1435	0.0530	2.7089	2.0438	3.5904
W05	W05.0XX A	Fall from non-moving wheelchair, initial encounter	660	0.1439	0.0532	2.7080	1.8148	4.0408
S98	S98.119 A	Complete traumatic amputation of unsp great toe, init encntr	1353	0.1434	0.0530	2.7069	2.0437	3.5853
R33	R33.9	Retention of urine, unspecified	20323	0.1307	0.0484	2.7009	2.4861	2.9343
C71	C71.9	Malignant neoplasm of brain, unspecified	557	0.1436	0.0532	2.7007	1.7462	4.1768
J47	J47.9	Bronchiectasis, uncomplicated	1749	0.1424	0.0529	2.6928	2.1001	3.4529
D53	D53.9	Nutritional anemia, unspecified	4238	0.1406	0.0522	2.6927	2.2886	3.1682
J44	J44.9	Chronic obstructive pulmonary disease, unspecified	63653	0.1089	0.0405	2.6858	2.5255	2.8563
I79	I79.8	Oth disord of art,arterioles & capilare in dis classd elswhr	940	0.1426	0.0531	2.6855	1.9159	3.7643
M80	M80.88X S	Oth osteopor w current path fracture, vertebra(e), sequela	1227	0.1418	0.0530	2.6752	1.9881	3.5997
I44	I44.0	Atrioventricular block, first degree	14983	0.1324	0.0497	2.6653	2.4270	2.9270
N26	N26.1	Atrophy of kidney (terminal)	757	0.1413	0.0531	2.6602	1.8232	3.8816
J80	J80.	Acute respiratory distress syndrome	1161	0.1404	0.0530	2.6474	1.9479	3.5981
C90	C90.00	Multiple myeloma not having achieved remission	1041	0.1402	0.0531	2.6431	1.9115	3.6547
C22	C22.0	Liver cell carcinoma	1150	0.1400	0.0530	2.6397	1.9385	3.5947
Y82	Y82.8	Other medical devices associated with adverse incidents	1007	0.1400	0.0531	2.6383	1.8972	3.6688
I35	I35.0	Nonrheumatic aortic (valve) stenosis	12454	0.1320	0.0503	2.6225	2.3688	2.9033
C32	C32.9	Malignant neoplasm of larynx, unspecified	930	0.1387	0.0531	2.6125	1.8504	3.6883
I08	I08.0	Rheumatic disorders of both mitral and aortic valves	3548	0.1370	0.0524	2.6117	2.1819	3.1263
E11	E11.9	Type 2 diabetes mellitus without complications	114394	0.0902	0.0346	2.6085	2.4536	2.7731
I22	I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	897	0.1382	0.0531	2.6031	1.8311	3.7006
I71	I71.4	Abdominal aortic aneurysm, without rupture	12513	0.1311	0.0504	2.6027	2.3505	2.8818
I21	I21.4	Non-ST elevation (NSTEMI) myocardial infarction	14174	0.1297	0.0500	2.5947	2.3550	2.8588
N04	N04.9	Nephrotic syndrome with unspecified morphologic changes	1098	0.1375	0.0531	2.5920	1.8837	3.5666
J94	J94.8	Other specified pleural conditions	726	0.1377	0.0531	2.5916	1.7519	3.8338
D04	D04.9	Carcinoma in situ of skin, unspecified	3845	0.1355	0.0524	2.5864	2.1733	3.0780
E87	E87.6	Hypokalemia	54353	0.1097	0.0426	2.5770	2.4185	2.7459
R60	R60.0	Localized edema	61977	0.1065	0.0415	2.5673	2.4126	2.7320
T45	T45.1X5 A	Adverse effect of antineoplastic and immunosup drugs, init	2220	0.1351	0.0528	2.5598	2.0383	3.2146
W01	W01.0XX A	Fall same lev from slip/trip w/o strike against object, init	9034	0.1311	0.0512	2.5594	2.2742	2.8805
C85	C85.80	Oth types of non-Hodgkin lymphoma, unspecified site	2228	0.1351	0.0528	2.5592	2.0386	3.2127

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

16

H34	H34.219	Partial retinal artery occlusion, unspecified eye	7070	0.1321	0.0517	2.5575	2.2414	2.9181
J18	J18.9	Pneumonia, unspecified organism	32422	0.1187	0.0464	2.5551	2.3768	2.7467
Z45	Z45.2	Encounter for adjustment and management of VAD	11371	0.1290	0.0507	2.5442	2.2854	2.8322
I74	I74.3	Embolism and thrombosis of arteries of the lower extremities	3254	0.1337	0.0526	2.5438	2.1033	3.0764
T86	T86.10	Unspecified complication of kidney transplant	1392	0.1343	0.0530	2.5349	1.9012	3.3798
E08	E08.42	Diabetes due to underlying condition w diabetic polyneurop	20437	0.1237	0.0488	2.5346	2.3283	2.7591
J93	J93.83	Other pneumothorax	1123	0.1345	0.0531	2.5341	1.8406	3.4889
A40	A40.9	Streptococcal sepsis, unspecified	789	0.1343	0.0531	2.5281	1.7269	3.7010
C67	C67.9	Malignant neoplasm of bladder, unspecified	4135	0.1323	0.0524	2.5266	2.1310	2.9956
C18	C18.9	Malignant neoplasm of colon, unspecified	4296	0.1318	0.0523	2.5179	2.1295	2.9771
T44	T44.7X5A	Adverse effect of beta-adrenoreceptor antagonists, init	831	0.1336	0.0531	2.5139	1.7318	3.6493
R27	R27.0	Ataxia, unspecified	5819	0.1306	0.0520	2.5125	2.1722	2.9061
Z93	Z93.3	Colostomy status	4186	0.1312	0.0524	2.5048	2.1131	2.9692
Z89	Z89.519	Acquired absence of unspecified leg below knee	5730	0.1302	0.0520	2.5031	2.1612	2.8992
Z43	Z43.3	Encounter for attention to colostomy	2992	0.1317	0.0526	2.5019	2.0489	3.0550
E10	E10.9	Type 1 diabetes mellitus without complications	20517	0.1220	0.0489	2.4951	2.2911	2.7172
H35	H35.31	Nonexudative age-related macular degeneration	60393	0.1051	0.0421	2.4933	2.3418	2.6547
I38	I38.	Endocarditis, valve unspecified	2607	0.1312	0.0527	2.4880	2.0084	3.0820
I24	I24.8	Other forms of acute ischemic heart disease	3221	0.1307	0.0526	2.4854	2.0481	3.0160
C25	C25.9	Malignant neoplasm of pancreas, unspecified	636	0.1321	0.0532	2.4835	1.6181	3.8117
I77	I77.1	Stricture of artery	7515	0.1280	0.0516	2.4789	2.1759	2.8241
R32	R32.	Unspecified urinary incontinence	18819	0.1220	0.0493	2.4746	2.2651	2.7034
I66	I66.9	Occlusion and stenosis of unspecified cerebral artery	883	0.1314	0.0531	2.4728	1.7165	3.5623
G12	G12.21	Amyotrophic lateral sclerosis	685	0.1314	0.0532	2.4710	1.6331	3.7387
I42	I42.9	Cardiomyopathy, unspecified	15337	0.1234	0.0500	2.4677	2.2418	2.7164
I72	I72.3	Aneurysm of iliac artery	3524	0.1294	0.0525	2.4632	2.0446	2.9675
I05	I05.8	Other rheumatic mitral valve diseases	1041	0.1306	0.0531	2.4607	1.7558	3.4485
F09	F09.	Unsp mental disorder due to known physiological condition	2150	0.1298	0.0528	2.4557	1.9380	3.1118
R77	R77.0	Abnormality of albumin	1284	0.1301	0.0530	2.4522	1.8076	3.3266
D62	D62.	Acute posthemorrhagic anemia	6406	0.1266	0.0519	2.4383	2.1167	2.8087
M86	M86.9	Osteomyelitis, unspecified	7523	0.1252	0.0517	2.4219	2.1227	2.7632
J43	J43.9	Emphysema, unspecified	9950	0.1238	0.0512	2.4182	2.1523	2.7169
I87	I87.2	Venous insufficiency (chronic) (peripheral)	23285	0.1175	0.0486	2.4162	2.2250	2.6239
M81	M81.0	Age-related osteoporosis w/o current pathological fracture	10016	0.1236	0.0512	2.4143	2.1494	2.7118
K72	K72.90	Hepatic failure, unspecified without coma	1867	0.1275	0.0529	2.4089	1.8641	3.1128
W19	W19.XX XA	Unspecified fall, initial encounter	21689	0.1178	0.0489	2.4085	2.2128	2.6214
D38	D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	1841	0.1271	0.0529	2.4015	1.8543	3.1101

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

17

T83	T83.098 A	Mech compl of other urinary catheter, initial encounter	3957	0.1259	0.0525	2.3983	2.0056	2.8679
I07	I07.1	Rheumatic tricuspid insufficiency	3276	0.1258	0.0526	2.3898	1.9643	2.9075
M31	M31.6	Other giant cell arteritis	1113	0.1267	0.0531	2.3863	1.7117	3.3268
T38	T38.0X5 A	Adverse effect of glucocort/synth analog, init	2095	0.1260	0.0529	2.3831	1.8674	3.0411
E09	E09.65	Drug or chemical induced diabetes mellitus w hyperglycemia	893	0.1265	0.0531	2.3814	1.6435	3.4506
E63	E63.9	Nutritional deficiency, unspecified	1355	0.1255	0.0530	2.3654	1.7469	3.2027
H90	H90.3	Sensorineural hearing loss, bilateral	118138	0.0855	0.0362	2.3616	2.2218	2.5102
I61	I61.9	Nontraumatic intracerebral hemorrhage, unspecified	1197	0.1253	0.0531	2.3610	1.7102	3.2595
G46	G46.4	Cerebellar stroke syndrome	4838	0.1234	0.0523	2.3586	2.0018	2.7791
R13	R13.10	Dysphagia, unspecified	40814	0.1080	0.0459	2.3554	2.1977	2.5245
C20	C20.	Malignant neoplasm of rectum	935	0.1251	0.0531	2.3552	1.6352	3.3920
E21	E21.3	Hyperparathyroidism, unspecified	4412	0.1233	0.0524	2.3526	1.9817	2.7930
K94	K94.23	Gastrostomy malfunction	1165	0.1245	0.0531	2.3446	1.6888	3.2551
S37	S37.009 A	Unspecified injury of unspecified kidney, initial encounter	989	0.1244	0.0531	2.3412	1.6399	3.3423
S81	S81.009 A	Unspecified open wound, unspecified knee, initial encounter	8362	0.1208	0.0516	2.3395	2.0586	2.6588
D89	D89.9	Disorder involving the immune mechanism, unspecified	1590	0.1239	0.0530	2.3378	1.7633	3.0995
G45	G45.9	Transient cerebral ischemic attack, unspecified	14740	0.1178	0.0504	2.3365	2.1140	2.5823
Y84	Y84.8	Oth medical procedures cause abn react/compl, w/o misadvnt	3576	0.1228	0.0526	2.3343	1.9295	2.8240
R47	R47.1	Dysarthria and anarthria	8462	0.1204	0.0516	2.3330	2.0539	2.6500
I45	I45.10	Unspecified right bundle-branch block	15283	0.1173	0.0503	2.3302	2.1113	2.5718
G81	G81.90	Hemiplegia, unspecified affecting unspecified side	3445	0.1225	0.0526	2.3279	1.9171	2.8267
R41	R41.2	Retrograde amnesia	42168	0.1065	0.0458	2.3270	2.1720	2.4930
I11	I11.9	Hypertensive heart disease without heart failure	28332	0.1117	0.0480	2.3255	2.1510	2.5142
Q84	Q84.5	Enlarged and hypertrophic nails	1698	0.1231	0.0530	2.3233	1.7664	3.0557
Q27	Q27.9	Congenital malformation of peripheral vascular system, unsp	1138	0.1230	0.0531	2.3170	1.6589	3.2362
J12	J12.9	Viral pneumonia, unspecified	1835	0.1226	0.0530	2.3155	1.7777	3.0160
T36	T36.8X5 A	Adverse effect of other systemic antibiotics, init encntr	1254	0.1228	0.0531	2.3139	1.6824	3.1826
I99	I99.8	Other disorder of circulatory system	4579	0.1212	0.0524	2.3130	1.9511	2.7419
S32	S32.009 A	Unsp fracture of unsp lumbar vertebra, init for clos fx	4732	0.1211	0.0524	2.3121	1.9555	2.7338
J95	J95.811	Postprocedural pneumothorax	2669	0.1218	0.0528	2.3067	1.8499	2.8763
D69	D69.6	Thrombocytopenia, unspecified	15284	0.1161	0.0504	2.3056	2.0880	2.5458
Z51	Z51.89	Encounter for other specified aftercare	178296	0.0729	0.0317	2.3027	2.1516	2.4644
Z99	Z99.89	Dependence on other enabling machines and devices	21756	0.1133	0.0492	2.3027	2.1125	2.5100
N05	N05.9	Unsp nephritic syndrome with unspecified morphologic changes	1450	0.1221	0.0530	2.3017	1.7091	3.0996

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

18

N03	N03.9	Chronic nephritic syndrome with unsp morphologic changes	736	0.1223	0.0532	2.2994	1.5164	3.4866
R34	R34.	Anuria and oliguria	720	0.1222	0.0532	2.2981	1.5085	3.5011
D09	D09.0	Carcinoma in situ of bladder	3148	0.1210	0.0527	2.2967	1.8724	2.8172
C76	C76.0	Malignant neoplasm of head, face and neck	3221	0.1208	0.0527	2.2923	1.8726	2.8061
I37	I37.0	Nonrheumatic pulmonary valve stenosis	1552	0.1211	0.0530	2.2847	1.7112	3.0505
Z94	Z94.0	Kidney transplant status	3033	0.1203	0.0527	2.2824	1.8526	2.8120
J16	J16.8	Pneumonia due to other specified infectious organisms	1240	0.1210	0.0531	2.2789	1.6494	3.1486
A04	A04.7	Enterocolitis due to Clostridium difficile	5175	0.1190	0.0523	2.2754	1.9351	2.6755
Z85	Z85.828	Personal history of other malignant neoplasm of skin	43622	0.1042	0.0458	2.2743	2.1233	2.4362
L60	L60.0	Ingrowing nail	53817	0.1007	0.0444	2.2688	2.1255	2.4219
H59	H59.032	Cystoid macular edema following cataract surgery, left eye	2323	0.1197	0.0529	2.2634	1.7830	2.8732
C77	C77.0	Sec and unsp malig neoplasm of nodes of head, face and neck	2569	0.1195	0.0528	2.2622	1.8024	2.8393
R53	R53.1	Weakness	65148	0.0971	0.0430	2.2599	2.1221	2.4067
E86	E86.0	Dehydration	28085	0.1091	0.0483	2.2594	2.0876	2.4453
T17	T17.300 A	Unsp foreign body in larynx causing asphyxiation, init	842	0.1200	0.0532	2.2563	1.5221	3.3445
R80	R80.3	Bence Jones proteinuria	13651	0.1142	0.0508	2.2489	2.0245	2.4983
Z79	Z79.899	Other long term (current) drug therapy	147374	0.0777	0.0346	2.2438	2.1065	2.3899
D47	D47.2	Monoclonal gammopathy	5592	0.1166	0.0523	2.2306	1.9049	2.6119
N31	N31.9	Neuromuscular dysfunction of bladder, unspecified	7306	0.1158	0.0520	2.2287	1.9386	2.5621
D50	D50.9	Iron deficiency anemia, unspecified	31287	0.1065	0.0479	2.2208	2.0569	2.3978
S51	S51.809 A	Unspecified open wound of unspecified forearm, init encntr	3177	0.1171	0.0527	2.2207	1.8053	2.7317
R15	R15.9	Full incontinence of feces	3962	0.1166	0.0526	2.2176	1.8405	2.6720
I34	I34.0	Nonrheumatic mitral (valve) insufficiency	11109	0.1137	0.0513	2.2167	1.9744	2.4887
I89	I89.0	Lymphedema, not elsewhere classified	5047	0.1161	0.0524	2.2165	1.8772	2.6172
H54	H54.7	Unspecified visual loss	25803	0.1080	0.0488	2.2108	2.0363	2.4001
I15	I15.8	Other secondary hypertension	4169	0.1161	0.0526	2.2092	1.8411	2.6510
R58	R58.	Hemorrhage, not elsewhere classified	1357	0.1172	0.0531	2.2077	1.6115	3.0243
D01	D01.0	Carcinoma in situ of colon	2376	0.1166	0.0529	2.2045	1.7352	2.8007
R63	R63.4	Abnormal weight loss	34666	0.1046	0.0475	2.2026	2.0448	2.3726
I36	I36.1	Nonrheumatic tricuspid (valve) insufficiency	3914	0.1157	0.0526	2.2002	1.8226	2.6561
J13	J13.	Pneumonia due to Streptococcus pneumoniae	1115	0.1166	0.0531	2.1948	1.5499	3.1081
N28	N28.9	Disorder of kidney and ureter, unspecified	27416	0.1067	0.0486	2.1941	2.0241	2.3783
I43	I43.	Cardiomyopathy in diseases classified elsewhere	1050	0.1162	0.0531	2.1867	1.5269	3.1315
D68	D68.8	Other specified coagulation defects	5690	0.1142	0.0523	2.1845	1.8648	2.5591
E83	E83.42	Hypomagnesemia	22641	0.1079	0.0494	2.1827	2.0014	2.3806
E16	E16.2	Hypoglycemia, unspecified	9251	0.1126	0.0517	2.1799	1.9207	2.4742
C44	C44.91	Basal cell carcinoma of skin, unspecified	21770	0.1080	0.0496	2.1778	1.9940	2.3785
H61	H61.23	Impacted cerumen, bilateral	58221	0.0966	0.0444	2.1776	2.0411	2.3232

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

19

I51	I51.7	Cardiomegaly	24480	0.1066	0.0492	2.1674	1.9918	2.3584
Z46	Z46.1	Encounter for fitting and adjustment of hearing aid	98123	0.0863	0.0399	2.1625	2.0355	2.2975
H52	H52.4	Presbyopia	192666	0.0694	0.0323	2.1442	2.0003	2.2985
D41	D41.4	Neoplasm of uncertain behavior of bladder	3097	0.1130	0.0528	2.1412	1.7289	2.6517
E20	E20.1	Pseudohypoparathyroidism	1647	0.1135	0.0530	2.1408	1.6002	2.8640
C61	C61.	Malignant neoplasm of prostate	19707	0.1069	0.0500	2.1359	1.9473	2.3427
K55	K55.20	Angiodysplasia of colon without hemorrhage	2499	0.1128	0.0529	2.1336	1.6821	2.7064
B96	B96.81	Helicobacter pylori as the cause of diseases classd elswhr	20262	0.1066	0.0500	2.1330	1.9466	2.3373
B95	B95.61	Methicillin suscep staph infct causing dis classd elswhr	13437	0.1086	0.0511	2.1267	1.9078	2.3708
N32	N32.81	Overactive bladder	19165	0.1063	0.0502	2.1188	1.9291	2.3272
E13	E13.9	Other specified diabetes mellitus without complications	11229	0.1089	0.0514	2.1177	1.8824	2.3824
T85	T85.398 A	Mech compl of ocular prosth dev/grft, init	3710	0.1113	0.0527	2.1128	1.7342	2.5739
I85	I85.00	Esophageal varices without bleeding	2480	0.1117	0.0529	2.1114	1.6608	2.6842
W18	W18.49X A	Oth slipping, tripping and stumbling w/o falling, init	13407	0.1077	0.0511	2.1079	1.8898	2.3511
R29	R29.6	Repeated falls	19639	0.1055	0.0501	2.1035	1.9164	2.3089
H02	H02.839	Dermatochalasis of unspecified eye, unspecified eyelid	29211	0.1024	0.0487	2.1019	1.9401	2.2772
B35	B35.1	Tinea unguium	95767	0.0854	0.0407	2.0963	1.9729	2.2274
G99	G99.0	Autonomic neuropathy in diseases classified elsewhere	4227	0.1100	0.0526	2.0908	1.7351	2.5194
K26	K26.9	Duodenal ulcer, unsp as acute or chronic, w/o hemor or perf	3428	0.1103	0.0527	2.0904	1.7008	2.5693
I31	I31.9	Disease of pericardium, unspecified	3328	0.1103	0.0528	2.0899	1.6953	2.5764
H49	H49.20	Sixth [abducent] nerve palsy, unspecified eye	1988	0.1107	0.0530	2.0883	1.5957	2.7330
T87	T87.89	Other complications of amputation stump	1707	0.1107	0.0530	2.0875	1.5620	2.7898
L62	L62.	Nail disorders in diseases classified elsewhere	1530	0.1105	0.0531	2.0813	1.5318	2.8279
N47	N47.6	Balanoposthitis	6273	0.1086	0.0523	2.0761	1.7776	2.4247
N39	N39.0	Urinary tract infection, site not specified	64087	0.0920	0.0444	2.0733	1.9446	2.2105
T46	T46.4X5 A	Adverse effect of angiotens-convert-enzyme inhibitors, init	1931	0.1098	0.0530	2.0712	1.5746	2.7244
Z16	Z16.11	Resistance to penicillins	2546	0.1092	0.0529	2.0638	1.6235	2.6234
I82	I82.409	Acute embolism and thombos unsp deep vn unsp lower extremity	14028	0.1046	0.0511	2.0456	1.8351	2.2803
N12	N12.	Tubulo-interstitial nephritis, not spcf as acute or chronic	1965	0.1084	0.0530	2.0449	1.5552	2.6887
S91	S91.309 A	Unspecified open wound, unspecified foot, initial encounter	11184	0.1054	0.0516	2.0447	1.8135	2.3054
H21	H21.81	Floppy iris syndrome	5158	0.1072	0.0525	2.0422	1.7199	2.4248
H01	H01.009	Unspecified blepharitis unspecified eye, unspecified eyelid	31384	0.0992	0.0487	2.0391	1.8843	2.2066
I97	I97.710	Intraoperative cardiac arrest during cardiac surgery	2682	0.1078	0.0529	2.0371	1.6095	2.5783
L85	L85.3	Xerosis cutis	31066	0.0991	0.0487	2.0350	1.8799	2.2029
M15	M15.9	Polyosteoarthritis, unspecified	70950	0.0892	0.0439	2.0333	1.9090	2.1656

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

20

I20	I20.8	Other forms of angina pectoris	31188	0.0990	0.0487	2.0318	1.8770	2.1993
N13	N13.30	Unspecified hydronephrosis	13082	0.1040	0.0513	2.0264	1.8109	2.2676
L57	L57.0	Actinic keratosis	46813	0.0945	0.0467	2.0227	1.8866	2.1685
G60	G60.9	Hereditary and idiopathic neuropathy, unspecified	30297	0.0988	0.0489	2.0219	1.8661	2.1907
M10	M10.9	Gout, unspecified	32778	0.0981	0.0485	2.0210	1.8693	2.1849
M1A	M1A.9XX 0	Chronic gout, unspecified, without tophus (tophi)	5350	0.1060	0.0525	2.0192	1.7039	2.3928
I26	I26.99	Other pulmonary embolism without acute cor pulmonale	7323	0.1051	0.0522	2.0148	1.7400	2.3330
K56	K56.60	Unspecified intestinal obstruction	8535	0.1047	0.0520	2.0141	1.7569	2.3090
G58	G58.9	Mononeuropathy, unspecified	20738	0.1011	0.0502	2.0134	1.8348	2.2093
D30	D30.3	Benign neoplasm of bladder	1931	0.1067	0.0530	2.0119	1.5228	2.6581
K59	K59.00	Constipation, unspecified	59540	0.0911	0.0453	2.0108	1.8833	2.1469
R01	R01.1	Cardiac murmur, unspecified	14466	0.1028	0.0511	2.0104	1.8045	2.2398
I47	I47.1	Supraventricular tachycardia	12549	0.1031	0.0514	2.0053	1.7873	2.2500
L11	L11.0	Acquired keratosis follicularis	16439	0.1020	0.0509	2.0047	1.8095	2.2209
I49	I49.9	Cardiac arrhythmia, unspecified	59805	0.0907	0.0453	2.0015	1.8746	2.1370
M62	M62.81	Muscle weakness (generalized)	71400	0.0882	0.0441	2.0014	1.8789	2.1319
G82	G82.20	Paraplegia, unspecified	2430	0.1058	0.0530	1.9973	1.5557	2.5643
J98	J98.4	Other disorders of lung	35483	0.0964	0.0483	1.9959	1.8494	2.1540
C64	C64.9	Malignant neoplasm of unsp kidney, except renal pelvis	3149	0.1048	0.0528	1.9829	1.5896	2.4736
H91	H91.90	Unspecified hearing loss, unspecified ear	71156	0.0876	0.0443	1.9790	1.8576	2.1083
E53	E53.8	Deficiency of other specified B group vitamins	19291	0.0996	0.0505	1.9712	1.7899	2.1710
R44	R44.0	Auditory hallucinations	4298	0.1038	0.0527	1.9697	1.6273	2.3841
R97	R97.2	Elevated prostate specific antigen [PSA]	36803	0.0950	0.0483	1.9694	1.8259	2.1241
R91	R91.8	Other nonspecific abnormal finding of lung field	37585	0.0947	0.0482	1.9658	1.8235	2.1193
H40	H40.009	Preglaucoma, unspecified, unspecified eye	61759	0.0889	0.0454	1.9583	1.8344	2.0905
I16	I16.0	Hypertensive urgency	5096	0.1024	0.0526	1.9481	1.6320	2.3254
Q61	Q61.00	Congenital renal cyst, unspecified	7172	0.1018	0.0523	1.9467	1.6744	2.2634
D49	D49.2	Neoplasm of unsp behavior of bone, soft tissue, and skin	14001	0.0998	0.0513	1.9437	1.7390	2.1726
Z76	Z76.0	Encounter for issue of repeat prescription	161461	0.0715	0.0369	1.9405	1.8214	2.0674
D07	D07.5	Carcinoma in situ of prostate	9818	0.1006	0.0519	1.9381	1.7008	2.2086
K74	K74.60	Unspecified cirrhosis of liver	8439	0.1010	0.0521	1.9372	1.6840	2.2285
K83	K83.1	Obstruction of bile duct	3048	0.1024	0.0529	1.9355	1.5416	2.4301
Z86	Z86.010	Personal history of colonic polyps	103774	0.0803	0.0415	1.9350	1.8211	2.0561
N42	N42.9	Disorder of prostate, unspecified	10264	0.1003	0.0519	1.9328	1.7003	2.1972
Y83	Y83.1	Implnt of artif int dev cause abn react/compl, w/o misadvnt	11053	0.0999	0.0518	1.9296	1.7044	2.1845
L84	L84.	Corns and callosities	31962	0.0946	0.0490	1.9284	1.7801	2.0891
R04	R04.0	Epistaxis	14831	0.0988	0.0513	1.9272	1.7282	2.1491
D72	D72.829	Elevated white blood cell count, unspecified	25660	0.0958	0.0499	1.9221	1.7619	2.0968
G93	G93.3	Postviral fatigue syndrome	39656	0.0925	0.0482	1.9201	1.7824	2.0685
B02	B02.9	Zoster without complications	16479	0.0976	0.0511	1.9118	1.7221	2.1225
Z92	Z92.3	Personal history of irradiation	8961	0.0994	0.0521	1.9092	1.6643	2.1900
N30	N30.00	Acute cystitis without hematuria	10151	0.0988	0.0519	1.9027	1.6710	2.1666
R78	R78.89	Finding of oth substances, not normally found in blood	32503	0.0933	0.0491	1.9012	1.7551	2.0595
R55	R55.	Syncope and collapse	30812	0.0937	0.0493	1.9004	1.7516	2.0619

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

21

E03	E03.9	Hypothyroidism, unspecified	35891	0.0925	0.0487	1.9000	1.7588	2.0526
H04	H04.123	Dry eye syndrome of bilateral lacrimal glands	82128	0.0830	0.0439	1.8911	1.7770	2.0126
K27	K27.9	Peptic ulc, site unsp, unsp as ac or chr, w/o hemor or perf	7919	0.0987	0.0522	1.8901	1.6332	2.1874
Z60	Z60.2	Problems related to living alone	11811	0.0974	0.0517	1.8817	1.6657	2.1257
E27	E27.9	Disorder of adrenal gland, unspecified	3916	0.0991	0.0528	1.8767	1.5290	2.3034
F06	F06.30	Mood disorder due to known physiological condition, unsp	31408	0.0926	0.0493	1.8761	1.7295	2.0351
Z65	Z65.9	Problem related to unspecified psychosocial circumstances	127694	0.0753	0.0401	1.8759	1.7653	1.9935
K25	K25.9	Gastric ulcer, unsp as acute or chronic, w/o hemor or perf	5442	0.0985	0.0526	1.8727	1.5718	2.2312
K86	K86.1	Other chronic pancreatitis	5781	0.0983	0.0526	1.8696	1.5768	2.2168
K68	K68.11	Postprocedural retroperitoneal abscess	4165	0.0984	0.0528	1.8654	1.5280	2.2774
H18	H18.51	Endothelial corneal dystrophy	11506	0.0961	0.0518	1.8546	1.6380	2.0999
T81	T81.89X A	Oth complications of procedures, NEC, init	10309	0.0957	0.0520	1.8411	1.6150	2.0989
D51	D51.9	Vitamin B12 deficiency anemia, unspecified	14069	0.0948	0.0515	1.8398	1.6416	2.0619
D29	D29.1	Benign neoplasm of prostate	6819	0.0963	0.0524	1.8370	1.5670	2.1535
Z44	Z44.8	Encounter for fit/adjust of external prosthetic devices	5211	0.0967	0.0527	1.8369	1.5333	2.2005
M84	M84.369 S	Stress fracture, unspecified tibia and fibula, sequela	5832	0.0965	0.0526	1.8362	1.5472	2.1791
C43	C43.9	Malignant melanoma of skin, unspecified	4224	0.0968	0.0528	1.8345	1.5020	2.2405
R82	R82.5	Elevated urine levels of drug/meds/biol subst	14186	0.0945	0.0515	1.8328	1.6357	2.0537
R35	R35.0	Frequency of micturition	39834	0.0890	0.0486	1.8321	1.6989	1.9756
L82	L82.1	Other seborrheic keratosis	55603	0.0859	0.0470	1.8281	1.7077	1.9571
Z91	Z91.19	Patient's noncompliance w oth medical treatment and regimen	64332	0.0842	0.0461	1.8244	1.7083	1.9482
R49	R49.0	Dysphonia	12308	0.0942	0.0518	1.8197	1.6114	2.0550
G62	G62.9	Polyneuropathy, unspecified	14108	0.0937	0.0516	1.8167	1.6201	2.0371
H43	H43.819	Vitreous degeneration, unspecified eye	38102	0.0887	0.0489	1.8155	1.6812	1.9606
I83	I83.90	Asymptomatic varicose veins of unspecified lower extremity	14263	0.0934	0.0516	1.8107	1.6154	2.0297
S22	S22.39X A	Fracture of one rib, unsp side, init for clos fx	10436	0.0942	0.0520	1.8102	1.5873	2.0644
S31	S31.000 A	Unsp opn wnd low back and pelv w/o penet retroperiton, init	10430	0.0942	0.0520	1.8093	1.5864	2.0635
Z13	Z13.6	Encounter for screening for cardiovascular disorders	237211	0.0616	0.0341	1.8054	1.6707	1.9509
K57	K57.30	Dvrtclos of lg int w/o perforation or abscess w/o bleeding	60553	0.0842	0.0466	1.8047	1.6880	1.9295
R06	R06.02	Shortness of breath	118999	0.0750	0.0417	1.7984	1.6926	1.9108
R09	R09.81	Nasal congestion	40481	0.0871	0.0488	1.7869	1.6567	1.9274
H31	H31.009	Unspecified chorioretinal scars, unspecified eye	9734	0.0931	0.0522	1.7845	1.5566	2.0458
Z23	Z23.	Encounter for immunization	260232	0.0594	0.0336	1.7694	1.6229	1.9292
D12	D12.0	Benign neoplasm of cecum	65120	0.0821	0.0465	1.7646	1.6519	1.8850
K92	K92.1	Melena	40170	0.0860	0.0489	1.7578	1.6287	1.8971
S01	S01.00X A	Unspecified open wound of scalp, initial encounter	7728	0.0921	0.0524	1.7574	1.5076	2.0485
L21	L21.9	Seborrheic dermatitis, unspecified	25335	0.0885	0.0505	1.7534	1.6012	1.9200

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

22

R79	R79.89	Other specified abnormal findings of blood chemistry	28403	0.0879	0.0502	1.7521	1.6065	1.9110
K80	K80.20	Calculus of gallbladder w/o cholecystitis w/o obstruction	16844	0.0896	0.0514	1.7429	1.5645	1.9417
R31	R31.9	Hematuria, unspecified	42562	0.0844	0.0489	1.7277	1.6025	1.8627
L03	L03.90	Cellulitis, unspecified	70833	0.0800	0.0463	1.7269	1.6183	1.8429
R42	R42.	Dizziness and giddiness	67634	0.0800	0.0467	1.7131	1.6040	1.8297
D48	D48.5	Neoplasm of uncertain behavior of skin	44749	0.0834	0.0488	1.7106	1.5883	1.8424
Z98	Z98.890	Other specified postprocedural states	92911	0.0763	0.0447	1.7083	1.6057	1.8174
R39	R39.15	Urgency of urination	29413	0.0858	0.0503	1.7069	1.5654	1.8611
K31	K31.89	Other diseases of stomach and duodenum	15241	0.0872	0.0517	1.6854	1.5028	1.8900
M89	M89.9	Disorder of bone, unspecified	17841	0.0863	0.0515	1.6760	1.5056	1.8657
R25	R25.2	Cramp and spasm	28206	0.0846	0.0505	1.6743	1.5323	1.8294
R69	R69.	Illness, unspecified	161563	0.0675	0.0405	1.6691	1.5685	1.7761
Z09	Z09.	Encntr for f/u exam aft trtmt for cond oth than malig neopl	55214	0.0803	0.0481	1.6682	1.5555	1.7891
Z48	Z48.02	Encounter for removal of sutures	78659	0.0770	0.0462	1.6660	1.5627	1.7760
M20	M20.40	Other hammer toe(s) (acquired), unspecified foot	43692	0.0811	0.0492	1.6482	1.5280	1.7779
L98	L98.9	Disorder of the skin and subcutaneous tissue, unspecified	55257	0.0784	0.0485	1.6182	1.5080	1.7365
M19	M19.90	Unspecified osteoarthritis, unspecified site	89625	0.0737	0.0460	1.6021	1.5046	1.7059
F12	F12.10	Cannabis abuse, uncomplicated	24113	0.0346	0.0548	0.6324	0.5463	0.7320
K58	K58.9	Irritable bowel syndrome without diarrhea	17352	0.0329	0.0544	0.6046	0.5071	0.7207
R51	R51.	Headache	51370	0.0335	0.0569	0.5896	0.5310	0.6546
L70	L70.0	Acne vulgaris	12335	0.0317	0.0541	0.5854	0.4739	0.7233
M22	M22.40	Chondromalacia patellae, unspecified knee	16168	0.0317	0.0544	0.5820	0.4835	0.7005
F15	F15.20	Other stimulant dependence, uncomplicated	8910	0.0300	0.0540	0.5554	0.4302	0.7168
Z56	Z56.0	Unemployment, unspecified	34996	0.0298	0.0560	0.5319	0.4661	0.6069
A63	A63.0	Anogenital (venereal) warts	4871	0.0279	0.0537	0.5199	0.3639	0.7428
T74	T74.21X A	Adult sexual abuse, confirmed, initial encounter	3385	0.0278	0.0536	0.5182	0.3376	0.7955
Z20	Z20.828	Contact w and exposure to oth viral communicable diseases	19317	0.0279	0.0549	0.5086	0.4243	0.6096
X50	X50.0XX A	Overexertion from strenuous movement or load, init	3150	0.0244	0.0536	0.4561	0.2838	0.7327
J03	J03.90	Acute tonsillitis, unspecified	5855	0.0243	0.0538	0.4505	0.3175	0.6391
A60	A60.9	Anogenital herpesviral infection, unspecified	7165	0.0241	0.0540	0.4475	0.3258	0.6145
Z31	Z31.5	Encounter for procreative genetic counseling	2984	0.0221	0.0536	0.4126	0.2471	0.6889
G43	G43.909	Migraine, unsp, not intractable, without status migrainosus	42103	0.0231	0.0576	0.4016	0.3503	0.4605
N95	N95.1	Menopausal and female climacteric states	9036	0.0216	0.0542	0.3982	0.2952	0.5371
R92	R92.8	Oth abn and inconclusive findings on dx imaging of breast	3749	0.0195	0.0537	0.3626	0.2225	0.5907
N60	N60.19	Diffuse cystic mastopathy of unspecified breast	3693	0.0187	0.0537	0.3479	0.2105	0.5748
A64	A64.	Unspecified sexually transmitted disease	6612	0.0180	0.0540	0.3331	0.2271	0.4886
N85	N85.8	Other specified noninflammatory disorders of uterus	3702	0.0170	0.0537	0.3167	0.1872	0.5360

COMORBIDITIES IN MODELS FOR COVID-19 DEATH

23

N46	N46.9	Male infertility, unspecified	2364	0.0161	0.0536	0.2999	0.1524	0.5904
N84	N84.1	Polyp of cervix uteri	1403	0.0157	0.0535	0.2932	0.1204	0.7138
N73	N73.9	Female pelvic inflammatory disease, unspecified	1373	0.0138	0.0535	0.2587	0.0992	0.6745
L68	L68.0	Hirsutism	1024	0.0127	0.0535	0.2375	0.0745	0.7569
N83	N83.20	Unspecified ovarian cysts	5025	0.0127	0.0539	0.2361	0.1400	0.3984
N89	N89.8	Other specified noninflammatory disorders of vagina	4793	0.0123	0.0539	0.2283	0.1324	0.3937
D25	D25.9	Leiomyoma of uterus, unspecified	4634	0.0123	0.0539	0.2282	0.1311	0.3972
N90	N90.7	Vulvar cyst	988	0.0121	0.0534	0.2272	0.0680	0.7594
F90	F90.9	Attention-deficit hyperactivity disorder, unspecified type	11738	0.0121	0.0548	0.2207	0.1552	0.3139
A74	A74.9	Chlamydial infection, unspecified	1082	0.0102	0.0535	0.1901	0.0539	0.6713
N76	N76.0	Acute vaginitis	10023	0.0098	0.0547	0.1789	0.1171	0.2733
E28	E28.2	Polycystic ovarian syndrome	2511	0.0088	0.0537	0.1633	0.0669	0.3987
N94	N94.6	Dysmenorrhea, unspecified	9013	0.0081	0.0546	0.1484	0.0908	0.2425
N92	N92.0	Excessive and frequent menstruation with regular cycle	9748	0.0081	0.0547	0.1483	0.0925	0.2377
N77	N77.1	Vaginitis, vulvitis and vulvovaginitis in dis classd elswhr	1805	0.0078	0.0536	0.1448	0.0473	0.4436
N72	N72.	Inflammatory disease of cervix uteri	1687	0.0071	0.0536	0.1328	0.0396	0.4452
R87	R87.619	Unsp abnormal cytolog findings in specmn from cervix uteri	6501	0.0071	0.0542	0.1305	0.0703	0.2422
N80	N80.9	Endometriosis, unspecified	2081	0.0067	0.0536	0.1255	0.0409	0.3846
N87	N87.9	Dysplasia of cervix uteri, unspecified	2020	0.0064	0.0536	0.1200	0.0375	0.3839
A56	A56.00	Chlamydial infection of lower genitourinary tract, unsp	1100	0.0064	0.0535	0.1190	0.0244	0.5801
N97	N97.9	Female infertility, unspecified	1964	0.0051	0.0536	0.0950	0.0252	0.3578
Z30	Z30.09	Encounter for oth general cnsl and advice on contraception	15303	0.0050	0.0556	0.0893	0.0551	0.1446
N91	N91.2	Amenorrhea, unspecified	2649	0.0042	0.0537	0.0773	0.0218	0.2740
N93	N93.9	Abnormal uterine and vaginal bleeding, unspecified	5282	0.0042	0.0541	0.0770	0.0315	0.1884
Z32	Z32.02	Encounter for pregnancy test, result negative	6339	0.0024	0.0543	0.0436	0.0147	0.1289
Z33	Z33.1	Pregnant state, incidental	3827	0.0010	0.0539	0.0194	0.0024	0.1585

**TABLE 2: MULTIVARIATE MODEL FOR COVID-19 DEATH BASED
UPON PRE-EXISTING CONDITIONS**

**Most Common ICD-10 Code and Description for Each Category Diagnosis*

***Ranked in Descending Order by Contribution to the Logit Function*

RootICD-10	ICD-10 Code*	ICD-10 Description*	Cases	Coefficient	Std Error	Z_Score	P_Value	Lower CI	Higher CI	Coeff_RR**
I10	I10.	Essential (primary) hypertension	208817	0.1934	0.0075	25.8300	0.0000	0.1787	0.2081	0.7424
J64	J64.	Unspecified pneumoconiosis	107	0.2495	0.1007	2.4800	0.0130	0.0521	0.4468	0.6695
F03	F03.90	Unspecified dementia without behavioral disturbance	13895	0.1619	0.0076	21.3500	0.0000	0.1471	0.1768	0.6683
C93	C93.10	Chronic myelomonocytic leukemia not achieve remission	122	0.2194	0.0815	2.6900	0.0070	0.0597	0.3791	0.6583
C24	C24.1	Malignant neoplasm of ampulla of Vater	122	0.2489	0.1006	2.4700	0.0130	0.0517	0.4461	0.6318
C71	C71.9	Malignant neoplasm of brain, unspecified	557	0.3400	0.0786	4.3300	0.0000	0.1860	0.4941	0.5782
C91	C91.10	Chronic lymphocytic leuk of B-cell type not achieve remis	1854	0.2492	0.0356	7.0000	0.0000	0.1794	0.3189	0.5362
G70	G70.00	Myasthenia gravis without (acute) exacerbation	745	0.2897	0.0625	4.6300	0.0000	0.1671	0.4122	0.5229
D46	D46.9	Myelodysplastic syndrome, unspecified	755	0.1633	0.0333	4.9000	0.0000	0.0980	0.2286	0.4858
L12	L12.0	Bullous pemphigoid	334	0.1955	0.0703	2.7800	0.0050	0.0577	0.3334	0.4425
C95	C95.90	Leukemia, unspecified not having achieved remission	609	0.1530	0.0476	3.2200	0.0010	0.0598	0.2463	0.4055
N18	N18.9	Chronic kidney disease, unspecified	48428	0.1663	0.0105	15.8500	0.0000	0.1457	0.1868	0.3998
G20	G20.	Parkinson's disease	5105	0.1656	0.0196	8.4500	0.0000	0.1272	0.2040	0.3912
C78	C78.7	Secondary malig neoplasm of liver and intrahepatic bile duct	1305	0.1545	0.0345	4.4700	0.0000	0.0868	0.2222	0.3834
G30	G30.9	Alzheimer's disease, unspecified	4348	0.0866	0.0107	8.0700	0.0000	0.0655	0.1076	0.3712
J84	J84.10	Pulmonary fibrosis, unspecified	7398	0.2074	0.0225	9.2100	0.0000	0.1633	0.2516	0.3634
C85	C85.80	Oth types of non-Hodgkin lymphoma, unspecified site	2228	0.2301	0.0451	5.1000	0.0000	0.1417	0.3185	0.3588
R18	R18.8	Other ascites	2408	0.1669	0.0335	4.9800	0.0000	0.1013	0.2325	0.3367
G11	G11.1	Early-onset cerebellar ataxia	586	0.1685	0.0640	2.6300	0.0080	0.0431	0.2939	0.3292
C34	C34.90	Malignant neoplasm of unsp part of unsp bronchus or lung	3805	0.1404	0.0272	5.1500	0.0000	0.0870	0.1938	0.3083
Z66	Z66.	Do not resuscitate	6448	0.0869	0.0105	8.2600	0.0000	0.0663	0.1075	0.3030
F02	F02.80	Dementia in oth diseases classd elswhr w/o behavrl disturb	8684	0.0775	0.0101	7.7100	0.0000	0.0578	0.0972	0.3028

R26	R26.9	Unspecified abnormalities of gait and mobility	67067	0.1327	0.0091	14.5100	0.0000	0.1148	0.1506	0.2996
C79	C79.51	Secondary malignant neoplasm of bone	2724	0.1445	0.0299	4.8300	0.0000	0.0859	0.2031	0.2994
G12	G12.21	Amyotrophic lateral sclerosis	685	0.2008	0.0842	2.3900	0.0170	0.0359	0.3658	0.2954
C22	C22.0	Liver cell carcinoma	1150	0.1762	0.0596	2.9600	0.0030	0.0594	0.2929	0.2889
D02	D02.20	Carcinoma in situ of unspecified bronchus and lung	2023	0.1246	0.0342	3.6500	0.0000	0.0577	0.1915	0.2875
C18	C18.9	Malignant neoplasm of colon, unspecified	4296	0.1874	0.0333	5.6300	0.0000	0.1221	0.2526	0.2845
R64	R64.	Cachexia	797	0.1066	0.0384	2.7800	0.0060	0.0313	0.1818	0.2820
N40	N40.0	Benign prostatic hyperplasia without lower urinary tract symp	85767	0.1412	0.0103	13.6600	0.0000	0.1209	0.1615	0.2615
C90	C90.00	Multiple myeloma not having achieved remission	1041	0.1577	0.0595	2.6500	0.0080	0.0411	0.2743	0.2591
I25	I25.10	Atherosclerotic heart disease of native coronary artery w/o ang pctrs	77259	0.1158	0.0095	12.1900	0.0000	0.0972	0.1344	0.2557
Z96	Z96.1	Presence of intraocular lens	58557	0.1228	0.0101	12.2200	0.0000	0.1031	0.1425	0.2537
E11	E11.9	Type 2 diabetes mellitus without complications	114394	0.1488	0.0118	12.5700	0.0000	0.1256	0.1720	0.2393
Z74	Z74.09	Other reduced mobility	17940	0.0917	0.0102	8.9500	0.0000	0.0716	0.1117	0.2368
L89	L89.90	Pressure ulcer of unspecified site, unspecified stage	8092	0.0834	0.0130	6.4000	0.0000	0.0579	0.1090	0.2350
C32	C32.9	Malignant neoplasm of larynx, unspecified	930	0.1421	0.0653	2.1700	0.0300	0.0140	0.2701	0.2291
J61	J61.	Pneumoconiosis due to asbestos and other mineral fibers	1189	0.1202	0.0467	2.5700	0.0100	0.0287	0.2116	0.2271
R54	R54.	Age-related physical debility	11357	0.0696	0.0096	7.2600	0.0000	0.0508	0.0884	0.2160
J44	J44.9	Chronic obstructive pulmonary disease, unspecified	63653	0.1281	0.0121	10.5500	0.0000	0.1043	0.1519	0.2160
I48	I48.91	Unspecified atrial fibrillation	35951	0.1048	0.0114	9.1600	0.0000	0.0824	0.1272	0.2035
I96	I96.	Gangrene, not elsewhere classified	2079	0.0857	0.0322	2.6600	0.0080	0.0225	0.1488	0.1925
I37	I37.0	Nonrheumatic pulmonary valve stenosis	1552	0.1488	0.0670	2.2200	0.0260	0.0175	0.2800	0.1912
E78	E78.5	Hyperlipidemia, unspecified	223873	0.0921	0.0127	7.2500	0.0000	0.0672	0.1170	0.1897
I71	I71.4	Abdominal aortic aneurysm, without rupture	12513	0.1183	0.0192	6.1800	0.0000	0.0808	0.1559	0.1896
I50	I50.9	Heart failure, unspecified	36427	0.0771	0.0102	7.5800	0.0000	0.0572	0.0971	0.1863
H25	H25.13	Age-related nuclear cataract, bilateral	127537	0.1014	0.0129	7.8700	0.0000	0.0762	0.1267	0.1799
I85	I85.00	Esophageal varices without bleeding	2480	0.1587	0.0712	2.2300	0.0260	0.0192	0.2983	0.1764
J96	J96.01	Acute respiratory failure with hypoxia	13350	0.0753	0.0135	5.5600	0.0000	0.0488	0.1019	0.1749
N19	N19.	Unspecified kidney failure	7383	0.0749	0.0170	4.4200	0.0000	0.0417	0.1082	0.1702
J47	J47.9	Bronchiectasis, uncomplicated	1749	0.0978	0.0454	2.1600	0.0310	0.0089	0.1867	0.1656
M81	M81.0	Age-related osteoporosis w/o current pathological fracture	10016	0.1163	0.0249	4.6700	0.0000	0.0675	0.1652	0.1645
D04	D04.9	Carcinoma in situ of skin, unspecified	3845	0.1033	0.0345	3.0000	0.0030	0.0357	0.1708	0.1639
H27	H27.8	Other specified disorders of lens	6825	0.0739	0.0173	4.2800	0.0000	0.0401	0.1078	0.1638

H90	H90.3	Sensorineural hearing loss, bilateral	118138	0.1200	0.0145	8.2600	0.0000	0.0915	0.1485	0.1634
E03	E03.9	Hypothyroidism, unspecified	35891	0.1812	0.0244	7.4300	0.0000	0.1334	0.2290	0.1631
D64	D64.9	Anemia, unspecified	62258	0.0916	0.0122	7.5300	0.0000	0.0677	0.1154	0.1576
B02	B02.9	Zoster without complications	16479	0.1667	0.0329	5.0700	0.0000	0.1022	0.2312	0.1520
N25	N25.81	Secondary hyperparathyroidism of renal origin	6475	0.0635	0.0191	3.3300	0.0010	0.0261	0.1008	0.1478
I73	I73.9	Peripheral vascular disease, unspecified	31350	0.0715	0.0114	6.2800	0.0000	0.0492	0.0938	0.1469
H61	H61.23	Impacted cerumen, bilateral	58221	0.1234	0.0162	7.6000	0.0000	0.0916	0.1552	0.1453
Z43	Z43.3	Encounter for attention to colostomy	2992	0.0951	0.0412	2.3100	0.0210	0.0144	0.1758	0.1428
H91	H91.90	Unspecified hearing loss, unspecified ear	71156	0.1438	0.0204	7.0600	0.0000	0.1039	0.1838	0.1408
H26	H26.9	Unspecified cataract	60786	0.0719	0.0110	6.5600	0.0000	0.0504	0.0933	0.1370
H35	H35.31	Nonexudative age-related macular degeneration	60393	0.0900	0.0132	6.8200	0.0000	0.0641	0.1158	0.1344
C67	C67.9	Malignant neoplasm of bladder, unspecified	4135	0.0867	0.0338	2.5600	0.0100	0.0203	0.1530	0.1324
Z95	Z95.1	Presence of aortocoronary bypass graft	34407	0.0659	0.0121	5.4600	0.0000	0.0422	0.0896	0.1317
R62	R62.7	Adult failure to thrive	3414	0.0395	0.0150	2.6400	0.0080	0.0102	0.0689	0.1295
J90	J90.	Pleural effusion, not elsewhere classified	5673	0.0519	0.0175	2.9600	0.0030	0.0176	0.0862	0.1257
R63	R63.4	Abnormal weight loss	34666	0.1042	0.0190	5.4700	0.0000	0.0669	0.1415	0.1253
J43	J43.9	Emphysema, unspecified	9950	0.0875	0.0256	3.4100	0.0010	0.0372	0.1377	0.1241
L97	L97.509	Non-pressure chronic ulcer oth prt unsp foot w unsp severity	13950	0.0648	0.0189	3.4300	0.0010	0.0278	0.1019	0.1181
R60	R60.0	Localized edema	61977	0.0741	0.0128	5.7900	0.0000	0.0490	0.0992	0.1161
C61	C61.	Malignant neoplasm of prostate	19707	0.0974	0.0262	3.7100	0.0000	0.0460	0.1489	0.1106
H54	H54.7	Unspecified visual loss	25803	0.0907	0.0203	4.4800	0.0000	0.0510	0.1303	0.1098
K74	K74.60	Unspecified cirrhosis of liver	8439	0.1148	0.0497	2.3100	0.0210	0.0175	0.2122	0.1076
D63	D63.1	Anemia in chronic kidney disease	14823	0.0421	0.0124	3.3900	0.0010	0.0177	0.0665	0.1073
N47	N47.6	Balanoposthitis	6273	0.0979	0.0421	2.3300	0.0200	0.0155	0.1804	0.1054
M10	M10.9	Gout, unspecified	32778	0.1014	0.0223	4.5400	0.0000	0.0576	0.1452	0.1035
I67	I67.89	Other cerebrovascular disease	16692	0.0534	0.0157	3.4000	0.0010	0.0226	0.0842	0.1021
I70	I70.0	Atherosclerosis of aorta	19489	0.0537	0.0147	3.6400	0.0000	0.0248	0.0825	0.1000
C44	C44.91	Basal cell carcinoma of skin, unspecified	21770	0.0769	0.0250	3.0800	0.0020	0.0280	0.1259	0.0906
I63	I63.9	Cerebral infarction, unspecified	18075	0.0507	0.0173	2.9400	0.0030	0.0169	0.0845	0.0905
T82	T82.818A	Embolism due to vascular prosth dev/grft, initial encounter	6593	0.0462	0.0232	1.9900	0.0470	0.0006	0.0917	0.0866
M15	M15.9	Polyosteoarthritis, unspecified	70950	0.0799	0.0191	4.1800	0.0000	0.0424	0.1173	0.0826
J18	J18.9	Pneumonia, unspecified organism	32422	0.0512	0.0155	3.3000	0.0010	0.0208	0.0817	0.0796
Z65	Z65.9	Problem related to unspecified psychosocial circumstances	127694	0.0833	0.0209	3.9800	0.0000	0.0423	0.1243	0.0730
I65	I65.29	Occlusion and stenosis of unspecified carotid artery	16848	0.0413	0.0162	2.5500	0.0110	0.0096	0.0729	0.0717
R01	R01.1	Cardiac murmur, unspecified	14466	0.0708	0.0309	2.2900	0.0220	0.0102	0.1313	0.0715
R33	R33.9	Retention of urine, unspecified	20323	0.0408	0.0164	2.4900	0.0130	0.0086	0.0729	0.0694

R32	R32.	Unspecified urinary incontinence	18819	0.0441	0.0192	2.2900	0.0220	0.0064	0.0817	0.0650
R80	R80.3	Bence Jones proteinuria	13651	0.0517	0.0262	1.9700	0.0490	0.0003	0.1030	0.0646
N17	N17.9	Acute kidney failure, unspecified	31785	0.0282	0.0123	2.2900	0.0220	0.0041	0.0523	0.0604
R97	R97.2	Elevated prostate specific antigen [PSA]	36803	0.0617	0.0248	2.4900	0.0130	0.0131	0.1103	0.0598
H02	H02.839	Dermatochalasis of unspecified eye, unspecified eyelid	29211	0.0526	0.0216	2.4300	0.0150	0.0102	0.0950	0.0580
L57	L57.0	Actinic keratosis	46813	0.0494	0.0226	2.1900	0.0290	0.0051	0.0937	0.0505
E87	E87.6	Hypokalemia	54353	0.0312	0.0138	2.2600	0.0240	0.0041	0.0583	0.0492
R91	R91.8	Other nonspecific abnormal finding of lung field	37585	-0.0542	0.0251	-2.1600	0.0310	-0.1035	-0.0049	-0.0523
I51	I51.7	Cardiomegaly	24480	-0.0507	0.0225	-2.2500	0.0240	-0.0948	-0.0066	-0.0592
R31	R31.9	Hematuria, unspecified	42562	-0.0824	0.0309	-2.6700	0.0080	-0.1430	-0.0219	-0.0600
R78	R78.89	Finding of oth substances, not normally found in blood	32503	-0.0692	0.0268	-2.5800	0.0100	-0.1217	-0.0166	-0.0624
Z09	Z09.	Encntr for f/u exam aft trtmt for cond oth than malig neoplms	55214	-0.0987	0.0319	-3.0900	0.0020	-0.1612	-0.0361	-0.0660
R42	R42.	Dizziness and giddiness	67634	-0.0950	0.0282	-3.3700	0.0010	-0.1503	-0.0398	-0.0677
R55	R55.	Syncope and collapse	30812	-0.0755	0.0277	-2.7200	0.0070	-0.1298	-0.0211	-0.0680
M62	M62.81	Muscle weakness (generalized)	71400	-0.0695	0.0206	-3.3700	0.0010	-0.1099	-0.0291	-0.0696
Z86	Z86.010	Personal history of colonic polyps	103774	-0.0745	0.0197	-3.7700	0.0000	-0.1132	-0.0358	-0.0697
N13	N13.30	Unspecified hydronephrosis	13082	-0.0708	0.0338	-2.1000	0.0360	-0.1369	-0.0046	-0.0727
I12	I12.9	Hypertensive chronic kidney disease w stg 1-4/unsp chr kdny	26422	-0.0329	0.0131	-2.5200	0.0120	-0.0585	-0.0073	-0.0762
E83	E83.42	Hypomagnesemia	22641	-0.0670	0.0234	-2.8700	0.0040	-0.1128	-0.0212	-0.0792
L03	L03.90	Cellulitis, unspecified	70833	-0.1097	0.0282	-3.8900	0.0000	-0.1651	-0.0544	-0.0797
L98	L98.9	Disorder of the skin and subcutaneous tissue, unspecified	55257	-0.1296	0.0345	-3.7600	0.0000	-0.1971	-0.0621	-0.0801
F06	F06.30	Mood disorder due to known physiological condition, unsp	31408	-0.0931	0.0291	-3.2000	0.0010	-0.1502	-0.0360	-0.0816
G93	G93.3	Postviral fatigue syndrome	39656	-0.0957	0.0253	-3.7800	0.0000	-0.1453	-0.0461	-0.0881
E86	E86.0	Dehydration	28085	-0.0714	0.0210	-3.4000	0.0010	-0.1126	-0.0302	-0.0899
Z79	Z79.899	Other long term (current) drug therapy	147374	-0.0736	0.0162	-4.5500	0.0000	-0.1054	-0.0419	-0.0915
D50	D50.9	Iron deficiency anemia, unspecified	31287	-0.0753	0.0208	-3.6200	0.0000	-0.1160	-0.0345	-0.0919
Z91	Z91.19	Patient's noncompliance w oth medical treatment and regimen	64332	-0.1130	0.0250	-4.5200	0.0000	-0.1620	-0.0640	-0.0932
K56	K56.60	Unspecified intestinal obstruction	8535	-0.0953	0.0406	-2.3500	0.0190	-0.1748	-0.0159	-0.0966
M20	M20.40	Other hammer toe(s) (acquired), unspecified foot	43692	-0.1552	0.0345	-4.5000	0.0000	-0.2228	-0.0875	-0.1006
I47	I47.1	Supraventricular tachycardia	12549	-0.1055	0.0346	-3.0500	0.0020	-0.1732	-0.0377	-0.1061
M19	M19.90	Unspecified osteoarthritis, unspecified site	89625	-0.1818	0.0320	-5.6800	0.0000	-0.2445	-0.1190	-0.1095
B95	B95.61	Methicillin suscep staph infct causing dis classd elswhr	13437	-0.1003	0.0321	-3.1300	0.0020	-0.1631	-0.0374	-0.1130
R25	R25.2	Cramp and spasm	28206	-0.1680	0.0389	-4.3200	0.0000	-0.2443	-0.0918	-0.1133

F05	F05.	Delirium due to known physiological condition	3612	-0.0458	0.0203	-2.2600	0.0240	-0.0855	-0.0061	-0.1148
J98	J98.4	Other disorders of lung	35483	-0.1159	0.0247	-4.6800	0.0000	-0.1644	-0.0674	-0.1154
S22	S22.39XA	Fracture of one rib, unsp side, init for clos fx	10436	-0.1438	0.0473	-3.0400	0.0020	-0.2366	-0.0511	-0.1165
K31	K31.89	Other diseases of stomach and duodenum	15241	-0.1706	0.0496	-3.4400	0.0010	-0.2679	-0.0734	-0.1169
G46	G46.4	Cerebellar stroke syndrome	4838	-0.0887	0.0379	-2.3400	0.0190	-0.1631	-0.0144	-0.1205
I11	I11.9	Hypertensive heart disease without heart failure	28332	-0.0920	0.0190	-4.8500	0.0000	-0.1291	-0.0548	-0.1219
I13	I13.0	Hyp hrt & chr kdny dis w hrt fail and stg 1-4/unsp chr kdny	9823	-0.0454	0.0133	-3.4100	0.0010	-0.0716	-0.0193	-0.1239
Z92	Z92.3	Personal history of irradiation	8961	-0.1416	0.0468	-3.0200	0.0030	-0.2334	-0.0498	-0.1287
H43	H43.819	Vitreous degeneration, unspecified eye	38102	-0.1599	0.0280	-5.7000	0.0000	-0.2148	-0.1049	-0.1304
Z48	Z48.02	Encounter for removal of sutures	78659	-0.1961	0.0303	-6.4800	0.0000	-0.2554	-0.1368	-0.1306
G81	G81.90	Hemiplegia, unspecified affecting unspecified side	3445	-0.0999	0.0456	-2.1900	0.0280	-0.1893	-0.0105	-0.1327
Y83	Y83.1	Implnt of artif int dev cause abn react/compl, w/o misadvnt	11053	-0.1500	0.0426	-3.5200	0.0000	-0.2335	-0.0666	-0.1394
D62	D62.	Acute posthemorrhagic anemia	6406	-0.1002	0.0306	-3.2800	0.0010	-0.1601	-0.0403	-0.1441
I20	I20.8	Other forms of angina pectoris	31188	-0.1400	0.0241	-5.8100	0.0000	-0.1872	-0.0928	-0.1445
R06	R06.02	Shortness of breath	118999	-0.1827	0.0247	-7.3900	0.0000	-0.2311	-0.1342	-0.1459
G62	G62.9	Polyneuropathy, unspecified	14108	-0.1832	0.0409	-4.4800	0.0000	-0.2635	-0.1030	-0.1496
Z13	Z13.6	Encounter for screening for cardiovascular disorders	237211	-0.1886	0.0286	-6.5900	0.0000	-0.2447	-0.1325	-0.1519
S91	S91.309A	Unspecified open wound, unspecified foot, initial encounter	11184	-0.1519	0.0374	-4.0600	0.0000	-0.2253	-0.0786	-0.1587
R39	R39.15	Urgency of urination	29413	-0.2332	0.0372	-6.2700	0.0000	-0.3061	-0.1604	-0.1648
Z98	Z98.890	Other specified postprocedural states	92911	-0.2348	0.0272	-8.6400	0.0000	-0.2881	-0.1815	-0.1663
T83	T83.098A	Mech compl of other urinary catheter, initial encounter	3957	-0.1205	0.0408	-2.9500	0.0030	-0.2004	-0.0406	-0.1685
H52	H52.4	Presbyopia	192666	-0.1513	0.0212	-7.1400	0.0000	-0.1928	-0.1097	-0.1731
I16	I16.0	Hypertensive urgency	5096	-0.2349	0.0548	-4.2900	0.0000	-0.3423	-0.1275	-0.2227
J16	J16.8	Pneumonia due to other specified infectious organisms	1240	-0.1815	0.0750	-2.4200	0.0160	-0.3285	-0.0345	-0.2321
Z23	Z23.	Encounter for immunization	260232	-0.3022	0.0320	-9.4500	0.0000	-0.3649	-0.2395	-0.2325
G21	G21.11	Neuroleptic induced parkinsonism	2043	-0.1384	0.0412	-3.3600	0.0010	-0.2193	-0.0576	-0.2494
I97	I97.710	Intraoperative cardiac arrest during cardiac surgery	2682	-0.2555	0.0660	-3.8700	0.0000	-0.3849	-0.1260	-0.2650
Z16	Z16.11	Resistance to penicillins	2546	-0.2529	0.0682	-3.7100	0.0000	-0.3866	-0.1192	-0.2690
T87	T87.89	Other complications of amputation stump	1707	-0.2549	0.0842	-3.0300	0.0020	-0.4199	-0.0899	-0.2772
W05	W05.0XXA	Fall from non-moving wheelchair, initial encounter	660	-0.1834	0.0706	-2.6000	0.0090	-0.3219	-0.0450	-0.3132

TABLE 3: COMPARISON OF METHODS FOR HANDLING COMORBIDITIES

	Charleston	Elixhauser	P(Death)Dx
Diagnosis-specific	No	No	Yes
Includes all relevant diagnosis	No	No	Yes
Number of comorbidities	19	30	—
Weighting	Arbitrary	None	Actual risk
Includes protective factors	No	Yes	Yes
Handles rare conditions	No	No	Yes
Effect of each comorbidity adjusted for others	No	No	Yes
Identifies all comorbid patterns and associated risks	No	No	Yes
Setting of extracted diagnostic codes	Inpatient only	Inpatient only	Inpatient/outpatient

REFERENCES

1. King JT Jr, Yoon JS, Rentsch CT, et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. *PLoS One*. 2020 Nov 11;15(11):e0241825. doi: 10.1371/journal.pone.0241825.
2. Ioannou GN, Green P, Fan VS, et al. "Development of COVIDVax model to estimate the risk of SARS-CoV-2-related death among 7.6 million US veterans for use in vaccination prioritization," *JAMA Network Open* 2021; 4:e214347.
3. Barda N, Riesel D, Akriv A, et al. Developing a COVID-19 mortality risk prediction model when individual-level data are not available. *Nature Communications* 2020. DOI: 10.1038/s41467-020-18297-9.
4. Hippisley-Cox J, Coupland CAC, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. *BMJ* 2021;374:n2244.
5. Cohn BA, Cirillo PM, Murphy CC, et al. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. *Science* 2021. DOI: 10.1126/science.abm0620.
6. Tuty Kuswardhani RA, Henrina J, Pranata R, Anthonius Lim M, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. *Diabetes Metab Syndr*. 2020 Nov-Dec;14(6):2103-2109. doi: 10.1016/j.dsx.2020.10.022. Epub 2020 Oct 28. PMID: 33161221.
7. Austin SR, Wong YN, Uzzo RG, Beck JR, Eggleston BL. Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score work. *Med Care*. 2015 Sep;53(9):e65-72. doi: 10.1097/MLR.0b013e318297429c.